Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus

Michael L. Cardenas, Christopher R. Spencer, Stephanie Markovina, Todd DeWees, Thomas R. Mazur, Ashley A. Weiner, Parag J. Parikh, Jeffrey R. Olsen

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography–(PET)/computed tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer. Quantitative pre- and posttreatment metrics that are predictive of recurrence are unknown. We evaluated the association between pre- and posttreatment FDG-PET/CT parameters and outcomes for patients with squamous cell carcinoma of the anus (SCCA). Methods and materials The records of 110 patients treated between 2003 and 2013 with definitive radiation therapy for SCCA were reviewed under an institutional review board–approved protocol. The median radiation therapy dose was 50.4 Gy (range, 35-60 Gy). Concurrent chemotherapy was administered for 109 of 110 patients and generally consisted of 5-fluorouracil and mitomycin C (n = 94). All patients underwent pretreatment FDG-PET/CT and 101 of 110 underwent posttreatment FDG-PET/CT 3 months after completion of radiation therapy. The maximum standard uptake value (SUVmax) was analyzed, in addition to multiple patient and treatment factors, by univariate and multivariate Cox regression for correlation with local recurrence (LR) and overall survival (OS). Results The median follow-up was 28.6 months. LR occurred in 1 of 15 (6.7%), 5 of 47 (10.6%), and 6 of 48 (12.5%) patients with stage I, II, and III disease, respectively. On univariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0095) and between increased OS and posttreatment SUVmax <6.1 (P = .0086). On multivariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0013) and the use of intensity modulated radiation therapy (P < .001). A significant multivariate association was observed between increased OS and posttreatment SUVmax <6.1 (P = .0373) and the use of 5-fluorouracil/mitomycin C chemotherapy (P = .001). Conclusion Posttreatment SUVmax <6.1 is associated with reduced LR and increased OS after chemoradiation therapy for SCCA independent of T and N stage on multivariate analysis. Greater follow-up is required to confirm this association with late patterns of failure.

Original languageEnglish (US)
Pages (from-to)281-287
Number of pages7
JournalAdvances in Radiation Oncology
Volume2
Issue number3
DOIs
StatePublished - Jul 1 2017
Externally publishedYes

Fingerprint

Anal Canal
Squamous Cell Carcinoma
Recurrence
Survival
Radiotherapy
Mitomycin
Fluorouracil
Multivariate Analysis
Anus Neoplasms
Drug Therapy
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. / Cardenas, Michael L.; Spencer, Christopher R.; Markovina, Stephanie; DeWees, Todd; Mazur, Thomas R.; Weiner, Ashley A.; Parikh, Parag J.; Olsen, Jeffrey R.

In: Advances in Radiation Oncology, Vol. 2, No. 3, 01.07.2017, p. 281-287.

Research output: Contribution to journalArticle

Cardenas, ML, Spencer, CR, Markovina, S, DeWees, T, Mazur, TR, Weiner, AA, Parikh, PJ & Olsen, JR 2017, 'Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus', Advances in Radiation Oncology, vol. 2, no. 3, pp. 281-287. https://doi.org/10.1016/j.adro.2017.04.007
Cardenas, Michael L. ; Spencer, Christopher R. ; Markovina, Stephanie ; DeWees, Todd ; Mazur, Thomas R. ; Weiner, Ashley A. ; Parikh, Parag J. ; Olsen, Jeffrey R. / Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus. In: Advances in Radiation Oncology. 2017 ; Vol. 2, No. 3. pp. 281-287.
@article{f4c9a49024854a0b955a5eddfc52c53a,
title = "Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus",
abstract = "Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography–(PET)/computed tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer. Quantitative pre- and posttreatment metrics that are predictive of recurrence are unknown. We evaluated the association between pre- and posttreatment FDG-PET/CT parameters and outcomes for patients with squamous cell carcinoma of the anus (SCCA). Methods and materials The records of 110 patients treated between 2003 and 2013 with definitive radiation therapy for SCCA were reviewed under an institutional review board–approved protocol. The median radiation therapy dose was 50.4 Gy (range, 35-60 Gy). Concurrent chemotherapy was administered for 109 of 110 patients and generally consisted of 5-fluorouracil and mitomycin C (n = 94). All patients underwent pretreatment FDG-PET/CT and 101 of 110 underwent posttreatment FDG-PET/CT 3 months after completion of radiation therapy. The maximum standard uptake value (SUVmax) was analyzed, in addition to multiple patient and treatment factors, by univariate and multivariate Cox regression for correlation with local recurrence (LR) and overall survival (OS). Results The median follow-up was 28.6 months. LR occurred in 1 of 15 (6.7{\%}), 5 of 47 (10.6{\%}), and 6 of 48 (12.5{\%}) patients with stage I, II, and III disease, respectively. On univariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0095) and between increased OS and posttreatment SUVmax <6.1 (P = .0086). On multivariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0013) and the use of intensity modulated radiation therapy (P < .001). A significant multivariate association was observed between increased OS and posttreatment SUVmax <6.1 (P = .0373) and the use of 5-fluorouracil/mitomycin C chemotherapy (P = .001). Conclusion Posttreatment SUVmax <6.1 is associated with reduced LR and increased OS after chemoradiation therapy for SCCA independent of T and N stage on multivariate analysis. Greater follow-up is required to confirm this association with late patterns of failure.",
author = "Cardenas, {Michael L.} and Spencer, {Christopher R.} and Stephanie Markovina and Todd DeWees and Mazur, {Thomas R.} and Weiner, {Ashley A.} and Parikh, {Parag J.} and Olsen, {Jeffrey R.}",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.adro.2017.04.007",
language = "English (US)",
volume = "2",
pages = "281--287",
journal = "Advances in Radiation Oncology",
issn = "2452-1094",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Quantitative FDG-PET/CT predicts local recurrence and survival for squamous cell carcinoma of the anus

AU - Cardenas, Michael L.

AU - Spencer, Christopher R.

AU - Markovina, Stephanie

AU - DeWees, Todd

AU - Mazur, Thomas R.

AU - Weiner, Ashley A.

AU - Parikh, Parag J.

AU - Olsen, Jeffrey R.

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography–(PET)/computed tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer. Quantitative pre- and posttreatment metrics that are predictive of recurrence are unknown. We evaluated the association between pre- and posttreatment FDG-PET/CT parameters and outcomes for patients with squamous cell carcinoma of the anus (SCCA). Methods and materials The records of 110 patients treated between 2003 and 2013 with definitive radiation therapy for SCCA were reviewed under an institutional review board–approved protocol. The median radiation therapy dose was 50.4 Gy (range, 35-60 Gy). Concurrent chemotherapy was administered for 109 of 110 patients and generally consisted of 5-fluorouracil and mitomycin C (n = 94). All patients underwent pretreatment FDG-PET/CT and 101 of 110 underwent posttreatment FDG-PET/CT 3 months after completion of radiation therapy. The maximum standard uptake value (SUVmax) was analyzed, in addition to multiple patient and treatment factors, by univariate and multivariate Cox regression for correlation with local recurrence (LR) and overall survival (OS). Results The median follow-up was 28.6 months. LR occurred in 1 of 15 (6.7%), 5 of 47 (10.6%), and 6 of 48 (12.5%) patients with stage I, II, and III disease, respectively. On univariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0095) and between increased OS and posttreatment SUVmax <6.1 (P = .0086). On multivariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0013) and the use of intensity modulated radiation therapy (P < .001). A significant multivariate association was observed between increased OS and posttreatment SUVmax <6.1 (P = .0373) and the use of 5-fluorouracil/mitomycin C chemotherapy (P = .001). Conclusion Posttreatment SUVmax <6.1 is associated with reduced LR and increased OS after chemoradiation therapy for SCCA independent of T and N stage on multivariate analysis. Greater follow-up is required to confirm this association with late patterns of failure.

AB - Purpose 18F-fluorodeoxyglucose (FDG) positron emission tomography–(PET)/computed tomography (CT) imaging is used for staging and treatment planning of patients with anal cancer. Quantitative pre- and posttreatment metrics that are predictive of recurrence are unknown. We evaluated the association between pre- and posttreatment FDG-PET/CT parameters and outcomes for patients with squamous cell carcinoma of the anus (SCCA). Methods and materials The records of 110 patients treated between 2003 and 2013 with definitive radiation therapy for SCCA were reviewed under an institutional review board–approved protocol. The median radiation therapy dose was 50.4 Gy (range, 35-60 Gy). Concurrent chemotherapy was administered for 109 of 110 patients and generally consisted of 5-fluorouracil and mitomycin C (n = 94). All patients underwent pretreatment FDG-PET/CT and 101 of 110 underwent posttreatment FDG-PET/CT 3 months after completion of radiation therapy. The maximum standard uptake value (SUVmax) was analyzed, in addition to multiple patient and treatment factors, by univariate and multivariate Cox regression for correlation with local recurrence (LR) and overall survival (OS). Results The median follow-up was 28.6 months. LR occurred in 1 of 15 (6.7%), 5 of 47 (10.6%), and 6 of 48 (12.5%) patients with stage I, II, and III disease, respectively. On univariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0095) and between increased OS and posttreatment SUVmax <6.1 (P = .0086). On multivariate analysis, a significant association was observed between reduced LR and posttreatment SUVmax <6.1 (P = .0013) and the use of intensity modulated radiation therapy (P < .001). A significant multivariate association was observed between increased OS and posttreatment SUVmax <6.1 (P = .0373) and the use of 5-fluorouracil/mitomycin C chemotherapy (P = .001). Conclusion Posttreatment SUVmax <6.1 is associated with reduced LR and increased OS after chemoradiation therapy for SCCA independent of T and N stage on multivariate analysis. Greater follow-up is required to confirm this association with late patterns of failure.

UR - http://www.scopus.com/inward/record.url?scp=85025606900&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025606900&partnerID=8YFLogxK

U2 - 10.1016/j.adro.2017.04.007

DO - 10.1016/j.adro.2017.04.007

M3 - Article

AN - SCOPUS:85025606900

VL - 2

SP - 281

EP - 287

JO - Advances in Radiation Oncology

JF - Advances in Radiation Oncology

SN - 2452-1094

IS - 3

ER -